FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3178750627> ?p ?o ?g. }

• W3178750627 abstract "Abstract Background Therapeutic targeting of host-cell factors required for SARS-CoV-2 entry is an alternative strategy to ameliorate COVID-19 severity. SARS-CoV-2 entry into lung epithelium requires the TMPRSS2 cell surface protease. Pre-clinical and correlative data in humans suggest that anti-androgenic therapies can reduce the expression of TMPRSS2 on lung epithelium. Accordingly, we hypothesize that therapeutic targeting of androgen receptor signaling via degarelix, a luteinizing hormone-releasing hormone (LHRH) antagonist, will suppress COVID-19 infection and ameliorate symptom severity. Methods This is a randomized phase 2, placebo-controlled, double-blind clinical trial in 198 patients to compare efficacy of degarelix plus best supportive care versus placebo plus best supportive care on improving the clinical outcomes of male Veterans who have been hospitalized due to COVID-19. Enrolled patients must have documented infection with SARS-CoV-2 based on a positive reverse transcriptase polymerase chain reaction result performed on a nasopharyngeal swab and have a severity of illness of level 3–5 (hospitalized but not requiring invasive mechanical ventilation). Patients stratified by age, history of hypertension, and severity are centrally randomized 2:1 (degarelix: placebo). The composite primary endpoint is mortality, ongoing need for hospitalization, or requirement for mechanical ventilation at 15 after randomization. Important secondary endpoints include time to clinical improvement, inpatient mortality, length of hospitalization, duration of mechanical ventilation, time to achieve a normal temperature, and the maximum severity of COVID-19 illness. Exploratory analyses aim to assess the association of cytokines, viral load, and various comorbidities with outcome. In addition, TMPRSS2 expression in target tissue and development of anti-viral antibodies will also be investigated. Discussion In this trial, we repurpose the FDA approved LHRH antagonist degarelix, commonly used for prostate cancer, to suppress TMPRSS2, a host cell surface protease required for SARS-CoV-2 cell entry. The objective is to determine if temporary androgen suppression with a single dose of degarelix improves the clinical outcomes of patients hospitalized due to COVID-19. Trial registration ClinicalTrials.gov NCT04397718. Registered on May 21, 2020" @default.
• W3178750627 created "2021-07-19" @default.
• W3178750627 creator A5001714656 @default.
• W3178750627 creator A5002702284 @default.
• W3178750627 creator A5004245154 @default.
• W3178750627 creator A5004670594 @default.
• W3178750627 creator A5006093336 @default.
• W3178750627 creator A5010679834 @default.
• W3178750627 creator A5011795261 @default.
• W3178750627 creator A5017096857 @default.
• W3178750627 creator A5017555522 @default.
• W3178750627 creator A5019037694 @default.
• W3178750627 creator A5019085328 @default.
• W3178750627 creator A5019725894 @default.
• W3178750627 creator A5028122762 @default.
• W3178750627 creator A5028238790 @default.
• W3178750627 creator A5029336572 @default.
• W3178750627 creator A5030205747 @default.
• W3178750627 creator A5033296492 @default.
• W3178750627 creator A5034444009 @default.
• W3178750627 creator A5034728230 @default.
• W3178750627 creator A5035802406 @default.
• W3178750627 creator A5035873625 @default.
• W3178750627 creator A5037951527 @default.
• W3178750627 creator A5046303192 @default.
• W3178750627 creator A5046387277 @default.
• W3178750627 creator A5047270486 @default.
• W3178750627 creator A5047770287 @default.
• W3178750627 creator A5054228964 @default.
• W3178750627 creator A5060371062 @default.
• W3178750627 creator A5062550407 @default.
• W3178750627 creator A5071509387 @default.
• W3178750627 creator A5080548546 @default.
• W3178750627 creator A5086121459 @default.
• W3178750627 creator A5088731078 @default.
• W3178750627 creator A5089959397 @default.
• W3178750627 date "2021-07-05" @default.
• W3178750627 modified "2023-10-06" @default.
• W3178750627 title "Hormonal intervention for the treatment of veterans with COVID-19 requiring hospitalization (HITCH): a multicenter, phase 2 randomized controlled trial of best supportive care vs best supportive care plus degarelix: study protocol for a randomized controlled trial" @default.
• W3178750627 cites W1972032770 @default.
• W3178750627 cites W2051827271 @default.
• W3178750627 cites W2087305232 @default.
• W3178750627 cites W2128379747 @default.
• W3178750627 cites W2912112870 @default.
• W3178750627 cites W2968356232 @default.
• W3178750627 cites W3009912996 @default.
• W3178750627 cites W3023316367 @default.
• W3178750627 cites W3110752337 @default.
• W3178750627 cites W3138930184 @default.
• W3178750627 cites W3156990363 @default.
• W3178750627 cites W837231054 @default.
• W3178750627 doi "https://doi.org/10.1186/s13063-021-05389-0" @default.
• W3178750627 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8256647" @default.
• W3178750627 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34225789" @default.
• W3178750627 hasPublicationYear "2021" @default.
• W3178750627 type Work @default.
• W3178750627 sameAs 3178750627 @default.
• W3178750627 citedByCount "5" @default.
• W3178750627 countsByYear W31787506272022 @default.
• W3178750627 countsByYear W31787506272023 @default.
• W3178750627 crossrefType "journal-article" @default.
• W3178750627 hasAuthorship W3178750627A5001714656 @default.
• W3178750627 hasAuthorship W3178750627A5002702284 @default.
• W3178750627 hasAuthorship W3178750627A5004245154 @default.
• W3178750627 hasAuthorship W3178750627A5004670594 @default.
• W3178750627 hasAuthorship W3178750627A5006093336 @default.
• W3178750627 hasAuthorship W3178750627A5010679834 @default.
• W3178750627 hasAuthorship W3178750627A5011795261 @default.
• W3178750627 hasAuthorship W3178750627A5017096857 @default.
• W3178750627 hasAuthorship W3178750627A5017555522 @default.
• W3178750627 hasAuthorship W3178750627A5019037694 @default.
• W3178750627 hasAuthorship W3178750627A5019085328 @default.
• W3178750627 hasAuthorship W3178750627A5019725894 @default.
• W3178750627 hasAuthorship W3178750627A5028122762 @default.
• W3178750627 hasAuthorship W3178750627A5028238790 @default.
• W3178750627 hasAuthorship W3178750627A5029336572 @default.
• W3178750627 hasAuthorship W3178750627A5030205747 @default.
• W3178750627 hasAuthorship W3178750627A5033296492 @default.
• W3178750627 hasAuthorship W3178750627A5034444009 @default.
• W3178750627 hasAuthorship W3178750627A5034728230 @default.
• W3178750627 hasAuthorship W3178750627A5035802406 @default.
• W3178750627 hasAuthorship W3178750627A5035873625 @default.
• W3178750627 hasAuthorship W3178750627A5037951527 @default.
• W3178750627 hasAuthorship W3178750627A5046303192 @default.
• W3178750627 hasAuthorship W3178750627A5046387277 @default.
• W3178750627 hasAuthorship W3178750627A5047270486 @default.
• W3178750627 hasAuthorship W3178750627A5047770287 @default.
• W3178750627 hasAuthorship W3178750627A5054228964 @default.
• W3178750627 hasAuthorship W3178750627A5060371062 @default.
• W3178750627 hasAuthorship W3178750627A5062550407 @default.
• W3178750627 hasAuthorship W3178750627A5071509387 @default.
• W3178750627 hasAuthorship W3178750627A5080548546 @default.
• W3178750627 hasAuthorship W3178750627A5086121459 @default.
• W3178750627 hasAuthorship W3178750627A5088731078 @default.
• W3178750627 hasAuthorship W3178750627A5089959397 @default.
• W3178750627 hasBestOaLocation W31787506271 @default.
• W3178750627 hasConcept C126322002 @default.
• W3178750627 hasConcept C142724271 @default.
• W3178750627 hasConcept C168563851 @default.
• W3178750627 hasConcept C177713679 @default.

• next